MeiraGTx price target raised to $14 from $12 at BofA

BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $14 from $12 and keeps a Buy rating on the shares, citing a strengthened cash position after announcing a strategic partnership with Hologen AI to expedite Meira’s phase 3-ready AAV-GAD for treatment of Parkinson’s. The firm views this deal as a positive providing upfront capital and helping to scale and optimize Meira’s “already strong manufacturing capabilities,” the analyst tells investors.